The contribution of bacteriophages to the aetiology and treatment of the bacterial vaginosis syndrome

Faculty reviews Pub Date : 2022-04-19 DOI:10.12703/r/11-8
Amaan Ali, J. S. Jørgensen, R. F. Lamont
{"title":"The contribution of bacteriophages to the aetiology and treatment of the bacterial vaginosis syndrome","authors":"Amaan Ali, J. S. Jørgensen, R. F. Lamont","doi":"10.12703/r/11-8","DOIUrl":null,"url":null,"abstract":"Bacteriophages are obligate intracellular viruses that parasitize bacteria, making use of the host biosynthetic machinery. Bacterial vaginosis (BV) causes serious adverse sequelae, such as sexually transmitted infections, seroconversion to HIV positivity, and preterm birth. The aetiology of BV is multifactorial, and the vaginal microbiota, the response to antibiotics, and the phenotypic outcomes differ between cases. The choice of antibiotics to treat BV depends on the clinician’s personal experience, which contributes to the poor outcome of BV treatment and high recurrence rate. In this review, we classify BV into two subtypes based on whether or not the BV case is sexually associated (potentially phage-related). An appropriate antibiotic can be selected on the basis of this BV-typing to optimise the short- and long-term effects of treatment. Not all Lactobacillus spp. are helpful or protective and some may sequestrate metronidazole, which mitigates its therapeutic efficacy. Phages, used therapeutically, could contribute to eubiosis by sparing beneficial species of Lactobacilli. However, Lactobacilli have an important role in maintaining vaginal eubiosis, so conventional wisdom has been that treatment of BV may benefit from metronidazole that conserves lactobacilli rather than clindamycin, which destroys lactobacilli. Furthermore, if the quality and quantity of vaginal lactobacilli are compromised by phage colonisation, as in the sexually transmitted subtype, eradication of lactobacilli with clindamycin followed by replacement by probiotics may be better therapeutically than metronidazole and reduce recurrence rates. Accordingly, the subtype of BV may provide a more scientific approach to antibiotic selection, which is absent in current clinical guidelines. We provide support for the role of bacteriophages in the aetiology, recurrence or failure to cure BV following treatment, through parasitic colonisation of lactobacilli that may be sexually transmitted and may be enhanced by other risk factors like smoking, a factor associated with BV.","PeriodicalId":73016,"journal":{"name":"Faculty reviews","volume":"93 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Faculty reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12703/r/11-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Bacteriophages are obligate intracellular viruses that parasitize bacteria, making use of the host biosynthetic machinery. Bacterial vaginosis (BV) causes serious adverse sequelae, such as sexually transmitted infections, seroconversion to HIV positivity, and preterm birth. The aetiology of BV is multifactorial, and the vaginal microbiota, the response to antibiotics, and the phenotypic outcomes differ between cases. The choice of antibiotics to treat BV depends on the clinician’s personal experience, which contributes to the poor outcome of BV treatment and high recurrence rate. In this review, we classify BV into two subtypes based on whether or not the BV case is sexually associated (potentially phage-related). An appropriate antibiotic can be selected on the basis of this BV-typing to optimise the short- and long-term effects of treatment. Not all Lactobacillus spp. are helpful or protective and some may sequestrate metronidazole, which mitigates its therapeutic efficacy. Phages, used therapeutically, could contribute to eubiosis by sparing beneficial species of Lactobacilli. However, Lactobacilli have an important role in maintaining vaginal eubiosis, so conventional wisdom has been that treatment of BV may benefit from metronidazole that conserves lactobacilli rather than clindamycin, which destroys lactobacilli. Furthermore, if the quality and quantity of vaginal lactobacilli are compromised by phage colonisation, as in the sexually transmitted subtype, eradication of lactobacilli with clindamycin followed by replacement by probiotics may be better therapeutically than metronidazole and reduce recurrence rates. Accordingly, the subtype of BV may provide a more scientific approach to antibiotic selection, which is absent in current clinical guidelines. We provide support for the role of bacteriophages in the aetiology, recurrence or failure to cure BV following treatment, through parasitic colonisation of lactobacilli that may be sexually transmitted and may be enhanced by other risk factors like smoking, a factor associated with BV.
噬菌体对细菌性阴道病综合征病因及治疗的贡献
噬菌体是专性细胞内病毒,寄生在细菌上,利用宿主的生物合成机制。细菌性阴道病(BV)会引起严重的不良后遗症,如性传播感染、血清转化为HIV阳性和早产。细菌性阴道炎的病因是多因素的,阴道微生物群、对抗生素的反应和表型结果因病例而异。治疗细菌性阴道炎的抗生素选择取决于临床医生的个人经验,这导致细菌性阴道炎治疗效果差,复发率高。在这篇综述中,我们根据BV病例是否与性相关(可能与噬菌体相关)将BV分为两种亚型。可以根据这种细菌性病毒分型选择适当的抗生素,以优化治疗的短期和长期效果。并非所有的乳酸菌都有帮助或保护作用,有些乳酸菌可能会隔离甲硝唑,从而降低其治疗效果。用于治疗的噬菌体可以通过保留有益的乳酸菌种类来促进益生菌。然而,乳酸菌在维持阴道益生菌中起着重要作用,因此传统观点认为细菌性阴道炎的治疗可能受益于甲硝唑,甲硝唑可以保存乳酸菌,而克林霉素可以破坏乳酸菌。此外,如果阴道乳酸菌的质量和数量受到噬菌体定植的影响,如在性传播亚型中,用克林霉素根除乳酸菌,然后用益生菌替代,可能比甲硝唑治疗效果更好,并降低复发率。因此,BV亚型可能为目前临床指南中缺乏的抗生素选择提供更科学的方法。我们通过乳酸菌的寄生定植,为噬菌体在细菌性感染的病因学、复发或治疗后无法治愈提供了支持。乳酸菌的寄生定植可能是性传播的,也可能因吸烟等其他危险因素而增强,吸烟是细菌性感染的一个相关因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信